SB 728 T

Drug Profile

SB 728 T

Alternative Names: CCR5-ZFN; SB 728mR T; SB-728-modified-T-cells; SB-728-T; SB-728-T-CCR5-gene-therapy; ZFP Therapeutic

Latest Information Update: 19 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics
  • Class Antivirals; Cell therapies; Gene therapies; T lymphocyte cell therapies; Zinc finger DNA binding proteins
  • Mechanism of Action CCR5 receptor modulators; Gene silencing; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 26 Sep 2018 Sangamo Therapeutics and Case Western Reserve University plans to initiate the phase I/II TRAILBLAZER trial in HIV infections (Treatment-experienced) in December 2018 (IV) (NCT03666871)
  • 13 Sep 2017 Phase-I/II development is ongoing in Puerto Rico (NCT01543152) (Sangamo Therapeutics pipeline, September 2017)
  • 07 Jul 2017 Sangamo Biosciences completes a phase I/II trial in HIV infections in USA and Puerto Rico (NCT01543152)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top